natgillin/translations-raw huggingface dataset:
preparation of a liquid pharmaceutical composition containing the complex of macrocyclic chelate with a lanthanide, free macrocyclic chelate that is not under the form of an excipient X[X',L] in which L is the macrocyclic chelate and X and X' are a metal ion, in particular chosen independently from calcium, sodium, zinc and magnesium, and/or free lanthanide, by mixing a solution of free DOTA as the free macrocyclic chelate and of free gadolinium as the free lanthanide, so as to obtain complexation of the lanthanide by the macrocyclic chelate, the amounts of free macrocyclic chelate and of free lanthanide being such that all the lanthanide is complexed and that Cch 1 > Ct ch 1, with Cch 1 representing the concentration of free macrocyclic chelate and Ct ch 1 representing the target concentration of the free macrocyclic chelate in the final liquid pharmaceutical formulation, Ct ch 1 being selected in the range of between 0.002 % and 0.4 % mol/mol; 
HR P20161312 T1 PATENTNI ZAHTJEVI Postupak za pripravu tekuće farmaceutske formulacije koja sadrži kompleks makrocikličkog kelata s lantanidom i mol/mol količinu slobodnog makrocikličkog kelata između 0.002% i 0.4%, te navedeni postupak sadrži sljedeće uzastopne korake: b) pripravu tekućeg farmaceutskog pripravka koji sadrži kompleks makrocikličkog kelata s lantanidom, te slobodni makrociklički kelat koji nije u obliku pomoćne tvari X[X',L] gdje L je makrociklički kelat i X i X' su metalni ion, naročito odabran neovisno od kalcija, natrija, cinka i magnezija, i/ili slobodnog lantanida, pomoću miješanja otopine slobodnog DOTA kao slobodnog makrocikličkog kelata 1 slobodnog gadolinija kao slobodnog lantanida, tako da se dobije kompleksirani lantanid pomoću makrocikličkog kelata,količine slobodnog makrocikličkog kelata 1 slobodnog lantanida su takve da se sav lantanid kompleksira 1 da Cal > Ceca
halogen, (C3-6)cycloalkyl, or and R2 together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocyclic ring containing at least 1 nitrogen atom or 1 nitrogen and 1 additional heteroatome e.g. selected from N or O, or 
R:iR, zajedno s atomom dušika na koji su priključeni tvore 5 do 7-člani heterociklički prsten koji sadrži barem 1 atom dušika ili 1 atom dušika i 1 dodatni heteroatom primjerice odabran od N ili O, ili R, je hidroksi i R, je formil;
The band intensity from a compound treatment was compared to its corresponding DMSO control and expressed as percent inhibition. 
Intenzitet pramena od tretmana spojem uspoređen je sa njegovim korespondirajućim DMSO kontrolom i izražen u postotku inhibicije.
detecting the presence of said antibody in said biological sample. A method of purifying from a sample NK cells bearing an inhibitory KIR on their cell surface comprising the steps of: contacting said sample with an antibody or antibody fragment according to claim 57 under conditions that allow said NK cells bearing an inhibitory KIR on their cell surface to bind to said antibody or antibody fragment, wherein said antibody or antibody fragment is conjugated or covalently bound to a solid support; and 
In vitro postupak otkrivanja prisutnosti NK stanica koje nose inhibitorni KIR na svojoj staničnoj površini u biološkom uzorku, taj postupak obuhvaća korake: a) kontakt biološkog uzorka s protutijelom ili fragmentom protutijela prema zahtjevu 57, gdje je to protutijelo ili fragment protutijela konjugirano ili kovalento vezano za spoj koji se može detektirati; i b) otkrivanje prisutnosti tog protutijela u biološkom uzorku.
The process of claim 1, wherein the second acid is hydrochloric acid. 
Postupak prema patentnom zahtjevu 2, pri čemu je kiselina u koraku vc, klorovodična kiselina.
wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) at least one compound selected from compounds known for their fungicidal activity; and a method of controlling diseases on useful plants, especially rust diseases on soybean plants. 
Pripravak koja je pogodan za kontrolu bolesti koje uzrokuju fitopatogeni, naznačen time što sadrži (A) spoj formule (I) pri čemu je R1 difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; te (B) spoj fenpropimorf.
Process variant (A) may be carried out using known methods (or analogously as hereinafter described in the Examples) for cleavage of carboxylic ester groups and can be carried out in situ after preparation of a compound of formula (I), where R6 is C1-C8-alkyl. 
Inačicu postupka (A) može se provesti primjenom poznatih metoda (ili analogno postupcima koji su opisani ovdje kasnije u primjerima) za odcjepljenje skupina karboksilnog estera i on se može provesti in situ nakon priprave spoja formule (1), u kojoj R" je C,-Cy-alkil.
depositing a parylene coating on the surface of the body; and 
(b) deponiranju parilenske obloge na površinu tijela; i
isolating dermal hair papilla fibroblasts (DPFs) from the DP by mechanically fixing said DP at the surface of a cell culture vessel, whereby the basal lamina is perforated to allow said DPFs migrating out, 
(b) izoliranja fibroblasta dermalne papile kose (DPF) iz DP pomoću mehaničkog učvršćivanja navedene DP na površini posude sa staničnom kulturom, pri čemu je bazična lamina perforirana kako bi se omogućila migracija DPF-ova prema van,
Flash cooling in the context of the present invention is carried out by allowing water to evaporate from the aqueous suspension under the action of heat contained in the suspension. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da je nakon koraka mljevenja c), vodena suspenzija mljevenog mineralnog materijala podvrgnuta koraku separacije, npr.
The pharmaceutical composition of claim 13, further comprising one or more inert, nontoxic, pharmaceutically suitable excipients. 
Farmaceutski pripravak prema jednom od zahtjeva 11 ili 12, naznačen time da sadrži jednu ili više inertnih, netoksičnih, farmaceutski pogodnih pomoćnih tvari.
Clause 8. The method of Clause 7, wherein the Mtb72f is a polypeptide consisting of residues 1 and 8-729 of SEQ ID NO:2 optionally with a His tag inserted following the initial Met residue. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 5, naznačen time što je fuzijski protein Mtb72f polpeptid koji se sastoji od ostataka 1 i 8-729 iz SEQ ID NO:2, izborno s ubačenim biljegom His iza početnog ostatka Met.
obtaining (S1909) the PLP identified by the PLP identifier in the layer-1 information and the data slice identified by the data slice identifier in the layer-1 information, wherein the PLP is mapped to a transport stream using the PLP identifier, the identifier of the transmission system, the information for a tuning frequency of the transmission system, the active OFDM symbol duration field and the guard interval field in the descriptor in the NIT; and 
dobivanje PLP-a koji odgovara identifikatoru PLP-a i identifikatoru sustava prijenosa uključenog u NIT; i dobivanje prijenosnog toka (transport stream, TS) prema kojem je PLP mapiran, gdje deskriptor dostavnog sustava prijenosa uključujući identifikator PLP-a, identifikator sustava prijenosa i aktivno polje trajanja simbola ortogonalne modulacijske tehnike u frekvencijskoj domeni (OFDM) u TS petlji NIT mapa prenosi tokove do PLP-ova u podatkovnim komadima sustava prijenosa.
The following illustrative Example of the invention involves contacting a calcium carbonate according to the process of the present invention, wherein the calcium carbonate is contacted with 10% of the at least one acid having a pKa of less than or equal to 2.5 and the time point of adding the at least one water soluble non-polymeric organic and/or inorganic weak acid is varied. 
Postupak prema zahtjevu 10, naznačen time da se kalcijev karbonat prvo dovodi u kontakt sa najmanje jednom kiselinom koja ima pK, od manje od ili jednako 2.5 1 nakon što je dodano 10 % ukupne količine navedene najmanje jedne kiseline koja ima pK, od manje od ili jednako 2.5, kalcijev karbonat se dovodi u kontakt sa barem jednom u
Use according to claim 13 wherein the immune system modulator is an interferon or chemically derivatized interferon. 
Primjena prema patentnom zahtjevu 13, naznačena time što je modulator imunogenog sistema interferon ili kemijski derivatizirani interferon.
In a further aspect of the invention a solid oral extended release pharmaceutical dosage form is provided that is bioequivalent to the commercial product Palladone™ as sold in the United States in 2005. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1 ili 2, naznačen time da je aktivni agens oksikodon hidroklorid i pri čemu oblik za doziranje kad je testiran u komparativnoj kliničkoj studiji je bioekvivalentan trgovačkom proizvodu OxyContin"".
The antisense oligonucleotide of claim 1, wherein the antisense oligonucleotide does not activate RNase H. 
Antisens oligonukleotid u skladu sa zahtjevom 1, naznačen time što navedeni antisens oligonukleotid ne aktivira RNazu H.
The terminal reducing sugar group of fructo-oligosaccharide is a glucose residue, which is less reactive in Maillard reaction than the terminal fructose residue of most of the oligofructose derived from inuline. 
Terminalna skupina reducirajućeg šećera frukto-oligosaharida je glukozni ostatak, koji je u Maillardovoj reakciji slabije reaktivan od fruktoznog terminalnog ostatka oligofruktozo dobivene iz inulina.
In a first sub-aspect, the crystallizing occurs at about room temperature. 
Postupak iz patentnog zahtjeva 2, u kome se kristalizacija događa na sobnoj temperaturi.
a compound of formula (I) wherein n represents 0, 
Spoj, naznačen time, da ima formulu (1) (i) gdje n predstavlja 0, 1, 2,3, 4ili 5, 10
is selected from 
R; je odabran između:
The composition according to claim 1, wherein the GPR119 agonist has an EC50 of less than 1 µM. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da GPRI 19 agonist ima EC50 manji od 1 uM.
The compound, tautomer or pharmaceutically acceptable salt thereof for use, according to claim 7 wherein the disease or disorder is ulcerative colitis. 
Spoj, njegov tautomer ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 7, naznačen time što je bolest 1li poremećaj ulcerozni kolitis.
The tire as claimed in claim 1, wherein the intermediate portion and the distal portion are of identical and homogeneous thickness. 
Pneumatska guma (1) u skladu s patentnim zahtjevom 1, naznačena time, da su srednji dio (133) i distalni dio (135) u biti jednake i homogene debljine.
In one embodiment, Ring A is a 5-membered carbocyclic ring and can be represented by Formula (Ig) as illustrated below: wherein each variable in Formula (Ig) has the same meaning as described herein, supra and infra. 
U jednom obliku, Prsten A je 5-člani karbociklički prsten i može se prikazati Formulom (Ig) prikazanom dolje: gdje svaka varijabla u Formuli (Ig) ima isto značenje kao što je opisano u tekstu, supra i infra.
lyophilizing the pharmaceutical product within the first chamber of the flexible bag to provide a lyophilized pharmaceutical product, 
prvu komoru (110) konfigurirana za držanje liofiliziranog farmaceutskog proizvoda;
a steam hose (11) which conveys the steam obtained in the steam boiler (8) to the cooking chamber (2), 
- < cijev za paru (11) koja provodi paru dobivenu u parnom kotlu (8) do komore za kuhanje (2),
Thus, the present invention can be used on existing boats, without the need to modify the existing circuitry provided on the boat. 
Tako se opisani izum može koristiti na postojećim plovilima, bez potrebe za promjenama na postojećim krugovima koji se nalaze na plovilu.
A colon cleansing solution comprising: to 800 mmol per litre ascorbate anion provided by a mixture of: 
Otopina za čišćenje debelog crijeva, naznačena time što sadrži: a) 300 do 800 mmol po litri askorbatnog aniona kojeg osigurava smjesa:
The radioactive metal-labeled anti-cadherin antibody according to any one of claims 1 to 9, wherein a mole ratio of the anti-cadherin antibody to the metal-chelating reagent is 1: 0.5 to 1: 3. 
Anti-P-kadherin antitijelo obilježeno radioaktivnim metalima u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time, da je molni omjer anti-P-kadherin antitijela u odnosu na reagens za keliranje metala od 1: 0,1 do 1: 4,5, poželjno 1: 0,5 do 1: 3.
a plurality of panels having a shape such that the plurality of panels are vertically stacked on top of each other in a closed state of the sectional door, and are horizontally stacked next to each other in a stored state of the sectional door; 
Sekcijska vrata (1) koja sadrže: mnoštvo ploča (2) koje imaju oblik tako da se mogu postavljati jedna na drugu u složenom stanju sekcijskih vrata, i jedna pored druge u pohranjenom stanju sekcijskih vrata;
reacting the bacterial saccharide-linker with a carrier protein to form a conjugate; 
reakcija kompleksa bakterijski saharid-spojnica s proteinskim nosačem kako bi se dobio konjugat;
Clastogenicity was predicted by determining the potential of compounds of interest to induce structural chromosome damage in Chinese hamster ovary (CHO) cells. 
Klastogenost je predviđena određivanjem potencijala spojeva od značaja da induciraju strukturna kromosomska oštećenja u stanicama jajnika kineskog hrčka (CHO).
L5A is an optionally substituted C2-4 alkylene. 
L** je po izboru supstituiran C,. alkilen.
assembling of said data sheet (4) with the remainder of the booklet. 
- < spajanje navedenih podatkovnih listova (4) s ostatkom knjižice.
perform uplink timing alignment based on the synchronous timing deviation information, in case that, in an uplink asynchronous status, the synchronous timing deviation information is included in the random access response (S02); 
Postupak obrade prema zahtjevu 5 ili 6, naznačen time da korak odbacivanja nadalje sadrži, u sinkronom statusu uzlazne veze, ne provođenje usklađivanja vremena uzlazne veze na osnovi informacije o odstupanju vremena sadržane u primljenom odgovoru slučajnog pristupa (S02).
An apparatus according to claim 4, wherein said adhesive applying means applies said first and said second adhesive portions together to form a strip of adhesive, said strip of adhesive extending along said first surface parallel to said first fold. 
Metoda u skladu s patentnim zahtjevom 4, pri čemu navedeni prvi i drugi prianjajući dijelovi zajedno oblikuju traku prianjajućeg produljenja duž navedene prve površine paralelno s navedenim prvim naborom.
having a bulk density of at least 0.2 g/mL, and/or 
ima prostornu gustoću od barem 0,3 g/ml, ili
In another aspect of the invention, the solvent is ethyl acetate. 
Poželjno, otapalo je etil acetat. HR P20080446 T3
The compound of any of claims 1 to 14, which is selected from the compounds of formula (Ia), (Ib), (Ic) and (Id): Wherein: 
Farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva 1 do 6, koja je odabrana od spoja sa formulom (Ia): (la) Gdje:
The composition of claim 23, wherein the disease that develops and/or progresses due to a decrease in the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII is von Willebrand disease. 
(d) se kod bolesti koja se razvija 1/ili se pojačava/napreduje zbog smanjenja ili deficijencije u aktivnosti krvnog koagulacijskog faktora VIII i/ili aktiviranog krvnog koagulacijskog faktora VIII, radi o von Willebrandovoj bolesti.
Q represents -O- group, -N--H or -N--CO-R10 group -where R10 stands for hydrogen atom, straight or branched C1-4 alkyl group, C3-6 cycloalkyl group, phenyl-, benzyl- or -NH-R11 group -where R11 represents straight or branched C1-4 alkyl group, C3-6 cycloalkyl group, phenyl- or benzyl-group-; and their salts and tautomers, desmotrops or optical isomers and the salts thereof. 
Q predstavlja -O– skupinu, -N–-H ili -N–-CO-R10 skupinu, gdje R10 predstavlja atom vodika, nerazgranatu ili razgranatu C1-4 alkilnu skupinu, C3-6 cikloalkilnu skupinu, fenilnu, benzilnu ili -NH-R11 skupinu, gdje R11 predstavlja nerazgranatu ili razgranatu C1-4 alkilnu skupinu, C3-6 cikloalkilnu skupinu, fenilnu ili benzilnu skupinu; i njihove soli i tautomeri, dezmotropi ili optički izomeri, kao i njihove soli.
The present invention encompasses compounds of the invention for reducing the insulin resistance and hyperglycemia in any or all of the above rodent diabetes models, in humans with type 2 diabetes or other preferred metabolic-related disorders or disorders of lipid metabolism described previously, or in models based on other mammals. 
Prikazani izum obuhvaća spojeve izuma za smanjenje inzulinske rezistencije i hiperglikemije u bilo kojem od gore navedenih modela dijabetesa glodavaca, kod ljudi s dijabetesom tipa 2 ili ostalim preferiranim metaboličkim poremećajima ili poremećajima metabolizma lipida opisanim ranije u tekstu, kao i kod modela na ostalim sisavcima.
A pharmaceutical composition adapted for oral administration comprising an effective amount of at least one pharmaceutically acceptable zinc salt in combination with an effective amount of an anti-H. pylori agent, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient. 
Farmaceutski pripravak za primjenu u želudac bolesnika, koji sadrži učinkovitu količinu barem jedne farmaceutski prikladne cinkove soli u kombinaciji s inhibitorom protonske pumpe, po izboru u kombinaciji s farmaceutski prikladnim nosačem, aditivom ili pomoćnom tvari za uporabu za brzo povećanje pH želučanih sokova u želucu bolesnika kojemu je to potrebno na barem 3.0 u vremenu ne većem od jednog sata nakon primjene.
For maintenance treatment, however, there are potential problems of a sublingual buprenorphine product for the treatment of opiate addicts, such as the requirement for frequent dosing. 
Ipak, za liječenje terapijom održavanja sublingvalnim buprenorfinom postoje mogući problemi za liječenje opijatnih ovisnika, kao što je potreba za čestim doziranjem.
A compound or pharmaceutically acceptable salt thereof, according to claim 3, wherein the compound is according to Formula IIIa, and L1 is absent or is -O-; W is C1-4 alkylene, or C2-4 alkenylene having one double bond. 
Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 3, naznačen time što je spoj u skladu s Formulom IIIa, a L1 je odsutan ili je -O-; W je C1-4 alkilen, ili C2-4 alkenilen s jednom dvostrukom vezom.
reacting the (C1-C6)alkyl-4-piperidinecarboxylate compound of the Formula III with di-tert-butyl dicarbonate in the presence of toluene or xylene to form a first mixture comprising toluene or xylene, tert-butanol and a compound of the Formula IV: 
(a) reakciju (CI-C6)alkil-4-piperidinkarboksilatnog spoja sa formulom III sa di-tert-butil dikarbonatom u prisutnosti toluena ili ksilena sa svrhom dobivanja prve mješavine koja obuhvaća toluen ili ksilen, test-butanol i spoj sa formulom TV:
means for introducing sludge into the sludge drying bed (14), comprising of valve controlled inlet pipe (9), 
(d) element za uvođenje mulja u ležište za sušenje mulja (14), koji se sastoji od ventilom kontrolirane ulazne cijevi (9);
The method of any one of claims 2-6, wherein the content of the acetone in the mixed solvent is more than 40%, or more than 50%, or more than 60%, or more than 70%, or more than 80%, or more than 90% by volume; wherein other solvent is an alcohol solvent, an ether solvent, a halogenated solvent, an ester solvent, a ketone solvent other than acetone, water or a combination thereof; wherein the alcohol solvent is a C1-C6 alcohol; the ether solvent is tetrahydrofuran, diethyl ether, dioxane, methyl tert -butyl ether, dimethoxyethane, diethylene glycol dimethyl ether, triethylene glycol dimethyl ether or a combination thereof; the halogenated solvent is dichloromethane, 1,2-dichloroethane, chloroform or a combination thereof; the ester solvent is ethyl acetate, isopropyl acetate, butyl acetate or a combination thereof; and the ketone solvent is butanone. 
Postupak prema bilo kojem od zahtjeva 1-5, naznačen time da je udio acetona u smjesi otapala veći od 40%, ili veći od 50%, ili veći od 60%, ili veći od 70%, ili veći od 80%, ili veći od 90% po volumenu; pri čemu drugo otapalo je alkoholno otapalo, etersko otapalo, halogenirano otapalo, estersko otapalo, ketonsko otapalo osim acetona, voda ili njihova kombinacija; pri čemu alkoholno otapalo je C,-C4 alkohol; etersko otapalo je tetrahidrofuran, dietil eter, dioksan, metil fert-butil eter, dimetoksietan, dietilen glikol dimetil eter, trietilen glikol dimetil eter ili njihova kombinacija; halogenirano otapalo je diklormetan, 1,2-dikloretan, kloroform ili njihova kombinacija; estersko otapalo je etil acetat, izopropil acetat, butil acetate ili njihova kombinacija; i ketonsko otapalo je butanon.
Stabilized pharmaceutical sub-micron suspensions and methods of forming same 
STABILIZIRANE FARMACEUTSKE SUBMIKRONSKE SUSPENZIJE I POSTUPCI NJIHOVE PROIZVODNJE
The tablet of claim 1, wherein the pharmaceutical composition provides a mean time to maximum plasma concentration (Tmax) of metformin of from 2.5 to 6.5 hours following administration before a meal. 
Farmaceutski sastav sukladno bilo kojem od zahtjeva 1 - 6, pri čemu farmaceutski sastav osigurava srednje vrijeme do maksimalne koncentracije u plazmi (Tmax) za metformin od oko 2.5 do 6.5 sati nakon primjene prije obroka.
In the case that the impurity was water, Na2SO4 was added to the solution, and the solution was filtered through filter paper into to a 2L flask. The solids were collected and washed with DCM (250mL) into the flask and the flask was covered with a septum and N2 balloon. 
U slučaju da je onečišćenje bila voda, otopini HR P20080057 T3 je bio dodao Na250., i otopina je bila filtrirana kroz papirnati filtar u tikvicu od 2 L. Otopina je bila ohlađena i isprana s DCM (250 mL) u tikvicu i tikvica je bila pokrivena sa dijafragmom i balonomN..
The system of claim 15, further comprising a seventh software module executable by the processor and the memory, the seventh software module configured to determine if the binary image of the portable executable file format includes a dynamic link library, a kernel driver, or an executable object. 
Sustav u skladu s patentnim zahtjevom 11, naznačen time što dodatno sadrži deveti programski modul, kojeg može izvršiti procesor s memorijom, gdje je deveti programski modul konfiguriran za usklađivanje ispravljene prijenosne izvršne datoteke.
preserving the Bordetella species in a bvg+ genotype in industrial culture, 
(i) očuvanju vrste iz roda Bordetella genotipa bvg+ u industrijskoj kulturi,
both microprocessors 6a, 6b interrupt transmission of the enabling signals to watchdog circuit 18, thus cutting off supply voltage Vdc to optoisolator 17 and so disabling passage of the telegrams to transmission stage 5; and 
- < oba mikroprocesora 6a, 6b prekidaju prijenos omogućujućih signala prema kontrolnim (watchdog) električkim krugovima 18, na taj način prekidajući opskrbu naponom Va. prema optoizolatoru 17 i tako onemogućujući prolaz telegrama prema prijenosnom podsklopu 5; i
having X-ray powder diffraction peaks at about 6.46, 7.91, 11.92, 12.26, 12.99, 14.19, 18.68, and 19.07 °2-Theta +/- 0.2, obtained at room temperature using a Cu source; and/or 
spoj ima maksimum DSC u svom DSC termogramu kod otprilike 195 °C i otprilike 245 °C; ili spoj ima maksimume difrakcije rendgenskih zraka na prahu kod otprilike 6,46, 7,91, 11,92, 12,26, 12,99, 14,19, 18,68, te 19,07 °2θ.
Pipe connector (RVS) according to any one of claims 1 to 6, wherein the first connection (AS1) and/or the second connection (AS2) are suitable for connecting pipe lines (RL), in particular by means of compression and/or a quick connect procedure. 
Konektor za cijevi (RVS) u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što su prvi spoj (AS1) iii drugi spoj (AS2) pogodni za spajanje cijevnih linija (RL), osobito komprimiranjem i/ili postupkom brzog spajanja.
wherein n is an integer from 0 to 20, and n<1> is an integer from 1 to 20; 
(M COOH gdje n jest cijeli broj od 0 do 20 te n' jest cijeli broj od 1 do 20,